UBS Group’s RAPTOR PHARMACEUTICAL CORP COM STK (DE) RPTP Stock Holding History

UBS Group’s Portfolio RPTP Stock Details RPTP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-15,000	Closed	-$78K	–	8907
2015 Q4	$78K	Hold	15,000	–	–	﹤0.01%	5424
2015 Q3	$91K	Hold	15,000	–	–	﹤0.01%	5316
2015 Q2	$237K	Sell	15,000 -60,000	-80%	-$729K	﹤0.01%	4727
2015 Q1	$815K	Buy	75,000 +73,900	+6,718%	+$754K	﹤0.01%	3747
2014 Q4	$12K	Buy	+1,100	New	+$10.7K	﹤0.01%	8282

UBS Group's RPTP Position: Q4 2016 in Review

UBS Group sold out of RAPTOR PHARMACEUTICAL CORP COM STK (DE) (RPTP) in Q4 2016, closing a stake of 2,100 shares — an estimated $19K sold.

UBS Group first reported a position in RPTP in Q4 2014 and held it in 8 quarters. The position peaked at $760K in Q4 2015. 0 funds tracked by Wall St. Rank hold RPTP as of Q4 2016.

UBS Group reported no remaining RAPTOR PHARMACEUTICAL CORP COM STK (DE) position as of Q4 2016 after selling out during the quarter.
UBS Group sold 2,100 RAPTOR PHARMACEUTICAL CORP COM STK (DE) shares in Q4 2016, an estimated $19K.
UBS Group first reported a position in RAPTOR PHARMACEUTICAL CORP COM STK (DE) in Q4 2014 and held it in 8 quarters.
UBS Group's RAPTOR PHARMACEUTICAL CORP COM STK (DE) position peaked at $760K in Q4 2015.
0 funds tracked by Wall St. Rank held RAPTOR PHARMACEUTICAL CORP COM STK (DE) as of Q4 2016.

Based on UBS Group's 13F filing for Q4 2016, filed 14 Feb 2017.